Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial

Rosiglitazone Decreases Bone Mass and Bone Marrow Fat

(2011) Torben Harsløf et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus?

(2011) Thomas Baum et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled Trial

(2010) Ugis Gruntmanis et al.   CALCIFIED TISSUE INTERNATIONAL

Caloric restriction leads to high marrow adiposity and low bone mass in growing mice

(2010) Maureen J Devlin et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro

(2009) Alexandre Elbaz et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study

(2009) Ian J. Douglas et al.   PLOS MEDICINE

Effect of increasing vertebral marrow fat content on BMD measurement, T-Score status and fracture risk prediction by DXA

(2008) G.M. Blake et al.   BONE

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

(2008) Y. K. Loke et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Thiazolidinedione-induced skeletal fragility - mechanisms and implications

(2008) Andrew Grey   DIABETES OBESITY & METABOLISM